Upstream Bio is a startup based in the United States, 2 tracked investors.
Upstream Bio is a company founded in 2018 headquartered in the United States. Brouky records 2 investors associated with the company.
Upstream Bio is developing verekitug, a clinical-stage antagonist targeting the TSLP receptor to treat chronic respiratory diseases driven by inflammation, such as severe asthma, CRSwNP, and COPD.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.